Sanofi Reports Positive Long-Term Data for AYVAKIT
Blueprint Medicines, a Sanofi company, announced positive four-year data from its PIONEER study on the drug AYVAKIT. The study showed the drug provides sustained benefits and has a strong long-term safety profile for patients with indolent systemic mastocytosis, a rare blood disorder. The company presented 12 datasets at the 2026 AAAAI Annual Meeting.
AYVAKIT is a targeted therapy that works by inhibiting KIT D816V, the genetic mutation that drives approximately 95% of cases of systemic mastocytosis. This mutation leads to the uncontrolled growth and activation of mast cells, which are a type of immune cell, causing a wide range of debilitating symptoms. The U.S. Food and Drug Administration (FDA) first approved AYVAKIT for adults with advanced systemic mastocytosis in June 2021. Its approval was expanded in May 2023 to include indolent systemic mastocytosis (ISM), the most common form of the disease, following positive results from the PIONEER trial. This made it the first and only medicine approved to treat ISM. The initial registrational data from the PIONEER trial showed that AYVAKIT led to significant improvements in patient-reported symptoms and reductions in mast cell burden compared to a placebo at 24 weeks. These results formed the basis of the drug's approval for this new, broader patient population. The acquisition of Blueprint Medicines by Sanofi was announced on June 2, 2025, and officially completed on July 18, 2025. The deal, valued at approximately $9.1 billion, brought AYVAKIT and Blueprint's expertise in mast cell diseases into Sanofi's immunology portfolio. The four-year follow-up data from the PIONEER study, presented at the 2026 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting, demonstrated that the benefits of AYVAKIT are sustained over the long term. Patients continued to experience meaningful symptom control and improvements in their quality of life with a consistent safety profile. In addition to the clinical trial data, a real-world study of AYVAKIT use in community practice settings also highlighted its effectiveness in improving symptoms for patients with indolent systemic mastocytosis. Long-term data has also suggested that treatment with avapritinib improves bone mineral density, a significant concern for patients with the disease.
